Amyloid –β pathology in Alzheimer’s disease: A nano delivery approach

[1]  D. V. Gowda,et al.  Development and Evaluation of Solid Lipid Nanoparticles for the Clearance of Aβ in Alzheimer’s Disease , 2023, Pharmaceutics.

[2]  A. John,et al.  Bilosomes as a Potential Carrier to Enhance Cognitive Effects of Bacopa monnieri Extract on Oral Administration , 2022, Journal of Health and Allied Sciences NU.

[3]  D. Bloom,et al.  Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: A value of statistical life approach , 2022, EClinicalMedicine.

[4]  Merhan E. Ali,et al.  A Brain-Targeted Approach to Ameliorate Memory Disorders in a Sporadic Alzheimer’s Disease Mouse Model via Intranasal Luteolin-Loaded Nanobilosomes , 2022, Pharmaceutics.

[5]  H. Abbas,et al.  The Tragedy of Alzheimer’s Disease: Towards Better Management via Resveratrol-Loaded Oral Bilosomes , 2021, Pharmaceutics.

[6]  Meenakshi Singh,et al.  A systematic review of carbohydrate-based bioactive molecules for Alzheimer's disease. , 2021, Future medicinal chemistry.

[7]  R. Taliyan,et al.  Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB , 2021, Pharmaceutics.

[8]  Tae-Eun Park,et al.  Recent advances with liposomes as drug carriers for treatment of neurodegenerative diseases , 2021, Biomedical Engineering Letters.

[9]  B. Dunn,et al.  Approval of Aducanumab for Alzheimer Disease-the FDA's Perspective. , 2021, JAMA internal medicine.

[10]  Yanan Liu,et al.  Multifunctional Selenium Quantum Dots for the Treatment of Alzheimer's Disease by Reducing Aβ-Neurotoxicity and Oxidative Stress and Alleviate Neuroinflammation. , 2021, ACS applied materials & interfaces.

[11]  Weiwei He,et al.  Emerging Nanotechnology for Treatment of Alzheimer’s and Parkinson’s Disease , 2021, Frontiers in Bioengineering and Biotechnology.

[12]  C. Li,et al.  Biomimetic Dendrimer–Peptide Conjugates for Early Multi‐Target Therapy of Alzheimer's Disease by Inflammatory Microenvironment Modulation , 2021, Advanced materials.

[13]  A. Atri,et al.  Aducanumab produced a clinically meaningful benefit in association with amyloid lowering , 2021, Alzheimer's Research & Therapy.

[14]  M. Abbas.  Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients , 2021, Polymers.

[15]  P. Kamla,et al.  Nanocarriers for Alzheimer’s disease: Research and patent update , 2021 .

[16]  M. Narayan,et al.  Carbon Quantum Dots for Treatment of Amyloid Disorders. , 2021, ACS applied nano materials.

[17]  Anjali Sharma,et al.  Dendrimer-tesaglitazar conjugate induces a phenotype shift of microglia and enhances β-amyloid phagocytosis. , 2020, Nanoscale.

[18]  D. Holtzman,et al.  Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol , 2020, Proceedings of the National Academy of Sciences.

[19]  T. Davis,et al.  Structure, Function, and Regulation of the Blood-Brain Barrier Tight Junction in Central Nervous System Disorders , 2020, Frontiers in Physiology.

[20]  A. Šarić,et al.  Identification of on- and off-pathway oligomers in amyloid fibril formation , 2020, Chemical science.

[21]  Ya-ru Huang,et al.  The Toxicity and Polymorphism of β-Amyloid Oligomers , 2020, International journal of molecular sciences.

[22]  T. P. Davis,et al.  Amyloidosis: Mitigation of Amyloidosis with Nanomaterials (Adv. Mater. 18/2020) , 2020 .

[23]  Tiziano Tuccinardi,et al.  The History of Nanoscience and Nanotechnology: From Chemical–Physical Applications to Nanomedicine , 2019, Molecules.

[24]  R. Morishita,et al.  Novel Method for Rapid Assessment of Cognitive Impairment Using High-Performance Eye-Tracking Technology , 2019, Scientific Reports.

[25]  M. Sakharkar,et al.  Benefits of curcumin in brain disorders , 2019, BioFactors.

[26]  A. Colell,et al.  Oxidative inactivation of amyloid beta-degrading proteases by cholesterol-enhanced mitochondrial stress , 2019, Redox biology.

[27]  Samantha Donnellan,et al.  Nanomedicines towards targeting intracellular Mtb for the treatment of tuberculosis , 2019, Journal of Interdisciplinary Nanomedicine.

[28]  M. Wolfe.  Structure and Function of the γ-Secretase Complex. , 2019, Biochemistry.

[29]  F. Sobott,et al.  Native Ion Mobility-Mass Spectrometry reveals the formation of β-barrel shaped Amyloid-β hexamers in a membrane-mimicking environment. , 2019, Journal of the American Chemical Society.

[30]  F. Maxfield,et al.  Lysosomal enzyme tripeptidyl peptidase 1 plays a role in degradation of beta amyloid fibrils , 2019, bioRxiv.

[31]  Seungpyo Hong,et al.  Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers , 2019, Experimental & Molecular Medicine.

[32]  J. Cladera,et al.  Poly(propylene imine) dendrimers with histidine-maltose shell as novel type of nanoparticles for synapse and memory protection. , 2019, Nanomedicine : nanotechnology, biology, and medicine.

[33]  T. Hyeon,et al.  Magnetite/Ceria Nanoparticle Assemblies for Extracorporeal Cleansing of Amyloid‐β in Alzheimer's Disease , 2019, Advanced materials.

[34]  Chan Beum Park,et al.  Multifunctional carbon dots as a therapeutic nanoagent for modulating Cu(ii)-mediated β-amyloid aggregation. , 2019, Nanoscale.

[35]  D. Michaelson,et al.  ApoE4: an emerging therapeutic target for Alzheimer’s disease , 2019, BMC Medicine.

[36]  Alzheimer's Association∗.  2019 Alzheimer's disease facts and figures , 2019, Alzheimer's & Dementia.

[37]  M. T. Caccamo,et al.  Smart Nanoparticles for Drug Delivery Application: Development of Versatile Nanocarrier Platforms in Biotechnology and Nanomedicine , 2019, Journal of Nanomaterials.

[38]  W. Ray,et al.  The Role of APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in Aging and Alzheimer’s Disease , 2019, Front. Aging Neurosci..

[39]  Hui Li,et al.  The Role of NMDA Receptors in Alzheimer’s Disease , 2019, Front. Neurosci..

[40]  T. P. Davis,et al.  Nucleation of β-rich oligomers and β-barrels in the early aggregation of human islet amyloid polypeptide. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[41]  Yilin Wang,et al.  Effects of Gold Nanospheres and Nanocubes on Amyloid-β Peptide Fibrillation. , 2019, Langmuir : the ACS journal of surfaces and colloids.

[42]  Z. Bian,et al.  Review of Current Strategies for Delivering Alzheimer’s Disease Drugs across the Blood-Brain Barrier , 2019, International journal of molecular sciences.

[43]  G. Phillips,et al.  Dendrimeric Poly(Epsilon-Lysine) Delivery Systems for the Enhanced Permeability of Flurbiprofen across the Blood-Brain Barrier in Alzheimer’s Disease , 2018, International journal of molecular sciences.

[44]  Z. Bozsó,et al.  Structural Optimization of Foldamer-Dendrimer Conjugates as Multivalent Agents against the Toxic Effects of Amyloid Beta Oligomers , 2018, Molecules.

[45]  C. Ho,et al.  In vitro neuroprotective effects of naringenin nanoemulsion against β-amyloid toxicity through the regulation of amyloidogenesis and tau phosphorylation. , 2018, International journal of biological macromolecules.

[46]  K. Ting,et al.  Current development of biodegradable polymeric materials for biomedical applications , 2018, Drug design, development and therapy.

[47]  E. Mufson,et al.  Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease , 2018, Neurobiology of Disease.

[48]  J. Herms,et al.  BACE1 Inhibitor MK-8931 Alters Formation but Not Stability of Dendritic Spines , 2018, Front. Aging Neurosci..

[49]  J. Udgaonkar,et al.  Structural mechanisms of oligomer and amyloid fibril formation by the prion protein. , 2018, Chemical communications.

[50]  Yin Luo,et al.  Exploring the Mechanism of Inhibition of Au Nanoparticles on the Aggregation of Amyloid-β(16-22) Peptides at the Atom Level by All-Atom Molecular Dynamics , 2018, International journal of molecular sciences.

[51]  J. Christie.  Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) for the Early Diagnosis of Dementia Across a Variety of Healthcare Settings , 2018, Issues in mental health nursing.

[52]  T. Loftsson,et al.  Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes , 2018, Molecules.

[53]  Michael K Danquah,et al.  Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations , 2018, Beilstein journal of nanotechnology.

[54]  H. Kalbitzer,et al.  Inhibition of amyloid Aβ aggregation by high pressures or specific d-enantiomeric peptides. , 2018, Chemical communications.

[55]  A. Silva,et al.  Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization , 2018, Journal of Nanobiotechnology.

[56]  C. Lyketsos,et al.  Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care , 2018, International Psychogeriatrics.

[57]  K. Nilsson,et al.  Amyloid fibril polymorphism: a challenge for molecular imaging and therapy , 2018, Journal of internal medicine.

[58]  G. Landreth,et al.  Nuclear receptor agonist-driven modification of inflammation and amyloid pathology enhances and sustains cognitive improvements in a mouse model of Alzheimer’s disease , 2018, Journal of Neuroinflammation.

[59]  M. Foley,et al.  Aminopyrimidine Class Aggregation Inhibitor Effectively Blocks Aβ-Fibrinogen Interaction and Aβ-Induced Contact System Activation. , 2018, Biochemistry.

[60]  Hong Zhang,et al.  Tau-Targeted Multifunctional Nanocomposite for Combinational Therapy of Alzheimer's Disease. , 2018, ACS nano.

[61]  H. Scheraga,et al.  Lysosomal enzyme tripeptidyl peptidase 1 destabilizes fibrillar Aβ by multiple endoproteolytic cleavages within the β-sheet domain , 2018, Proceedings of the National Academy of Sciences.

[62]  Xueji Zhang,et al.  Synergistic Inhibitory Effect of GQDs-Tramiprosate Covalent Binding on Amyloid Aggregation. , 2018, ACS chemical neuroscience.

[63]  X. Jing,et al.  Curcumin-loaded PLGA-PEG nanoparticles conjugated with B6 peptide for potential use in Alzheimer’s disease , 2018, Drug delivery.

[64]  D. Choi,et al.  Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease , 2018, Drug delivery.

[65]  Xufeng Zhu,et al.  Sulfur Nanoparticles with Novel Morphologies Coupled with Brain-Targeting Peptides RVG as a New Type of Inhibitor Against Metal-Induced Aβ Aggregation. , 2017, ACS chemical neuroscience.

[66]  K. Pandima Devi,et al.  Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer’s toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function , 2017, Artificial cells, nanomedicine, and biotechnology.

[67]  A. Saleh,et al.  Applications of nanoparticle systems in drug delivery technology , 2017, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[68]  A. Camins,et al.  Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein. , 2018, Neurologia.

[69]  P. Yip,et al.  Detection of cognitive impairment using self-rated AD8 and informant-reported AD8. , 2018, Journal of the Formosan Medical Association = Taiwan yi zhi.

[70]  J. Kuźnicki,et al.  Knockdown of amyloid precursor protein increases calcium levels in the endoplasmic reticulum , 2017, Scientific Reports.

[71]  Xu Chen,et al.  Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid β aggregation for treating Alzheimer's disease. , 2017, Journal of colloid and interface science.

[72]  E. Giralt,et al.  Peptide multifunctionalized gold nanorods decrease toxicity of β-amyloid peptide in a Caenorhabditis elegans model of Alzheimer's disease. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[73]  Yu-jiong Wang,et al.  PLGA nanoparticles modified with a BBB-penetrating peptide co-delivering Aβ generation inhibitor and curcumin attenuate memory deficits and neuropathology in Alzheimer's disease mice , 2017, Oncotarget.

[74]  C. Jack,et al.  Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers , 2017, The Lancet Neurology.

[75]  S. Réhman,et al.  Enhanced neuroprotection of anthocyanin-loaded PEG-gold nanoparticles against Aβ1-42-induced neuroinflammation and neurodegeneration via the NF-KB /JNK/GSK3β signaling pathway. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[76]  Ping Zhou,et al.  Brain Perivascular Macrophages Initiate the Neurovascular Dysfunction of Alzheimer A&bgr; Peptides , 2017, Circulation research.

[77]  M. Cascella,et al.  The efficacy of Epigallocatechin-3-gallate (green tea) in the treatment of Alzheimer’s disease: an overview of pre-clinical studies and translational perspectives in clinical practice , 2017, Infectious Agents and Cancer.

[78]  C. Jack,et al.  A phase 3 trial of IV immunoglobulin for Alzheimer disease , 2017, Neurology.

[79]  Y. Kuo,et al.  Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin , 2017, International journal of nanomedicine.

[80]  K. Seppi,et al.  Magnetic resonance imaging for the diagnosis of Parkinson’s disease , 2017, Journal of Neural Transmission.

[81]  Taolei Sun,et al.  The size-effect of gold nanoparticles and nanoclusters in the inhibition of amyloid-β fibrillation. , 2017, Nanoscale.

[82]  T. Deller,et al.  Regulation of Alpha-Secretase ADAM10 In vitro and In vivo: Genetic, Epigenetic, and Protein-Based Mechanisms , 2017, Front. Mol. Neurosci..

[83]  J. Herz,et al.  Functional Roles of the Interaction of APP and Lipoprotein Receptors , 2017, Front. Mol. Neurosci..

[84]  K. Black,et al.  Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes , 2017, Cellular and Molecular Life Sciences.

[85]  A. Neves,et al.  Resveratrol and Grape Extract-loaded Solid Lipid Nanoparticles for the Treatment of Alzheimer’s Disease , 2017, Molecules.

[86]  Deepti Goyal,et al.  Rationally Designed Peptides and Peptidomimetics as Inhibitors of Amyloid-β (Aβ) Aggregation: Potential Therapeutics of Alzheimer's Disease. , 2017, ACS combinatorial science.

[87]  A. Jong,et al.  Alpha7 nicotinic acetylcholine receptor is required for amyloid pathology in brain endothelial cells induced by Glycoprotein 120, methamphetamine and nicotine , 2017, Scientific Reports.

[88]  P. Reddy,et al.  Amyloid-Beta and Phosphorylated Tau Accumulations Cause Abnormalities at Synapses of Alzheimer's disease Neurons. , 2017, Journal of Alzheimer's disease : JAD.

[89]  Norelle C. Wildburger,et al.  Soluble Amyloid-beta Aggregates from Human Alzheimer’s Disease Brains , 2016, Scientific Reports.

[90]  L. Fenart,et al.  Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases , 2016, Molecules.

[91]  E. Tao,et al.  Graphene quantum dots conjugated neuroprotective peptide improve learning and memory capability. , 2016, Biomaterials.

[92]  D. B. Vieira,et al.  Getting into the brain: liposome-based strategies for effective drug delivery across the blood–brain barrier , 2016, International journal of nanomedicine.

[93]  M. Gairí,et al.  Aβ42 assembles into specific β-barrel pore-forming oligomers in membrane-mimicking environments , 2016, Proceedings of the National Academy of Sciences.

[94]  Yan Zhou,et al.  Cerebral Blood Flow Alterations as Assessed by 3D ASL in Cognitive Impairment in Patients with Subcortical Vascular Cognitive Impairment: A Marker for Disease Severity , 2016, Front. Aging Neurosci..

[95]  W. Cerpa,et al.  Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies , 2016, Neural plasticity.

[96]  Raquel Ferreira,et al.  Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[97]  Bin-bo Jiang,et al.  HP-β-cyclodextrin as an inhibitor of amyloid-β aggregation and toxicity. , 2016, Physical chemistry chemical physics : PCCP.

[98]  H. Soares,et al.  The γ-Secretase Modulator, BMS-932481, Modulates Aβ Peptides in the Plasma and Cerebrospinal Fluid of Healthy Volunteers , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[99]  H. Soares,et al.  Robust Translation of γ-Secretase Modulator Pharmacology across Preclinical Species and Human Subjects , 2016, The Journal of Pharmacology and Experimental Therapeutics.

[100]  C. Fardella,et al.  Role of the Renin-Angiotensin-Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hypertension , 2016, International journal of molecular sciences.

[101]  D. Hill,et al.  Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials , 2016, Alzheimer's Research & Therapy.

[102]  Mehrdad Hamidi,et al.  Cubosomes: remarkable drug delivery potential. , 2016, Drug discovery today.

[103]  Michele Vendruscolo,et al.  Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation , 2016, Nature Communications.

[104]  E. Liu,et al.  First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer’s disease , 2016, Alzheimer's Research & Therapy.

[105]  Wei-Jen Tang.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus , 2016, Trends in Endocrinology & Metabolism.

[106]  Barbara Ruozi,et al.  Nanoparticle transport across the blood brain barrier , 2016, Tissue barriers.

[107]  E. Liu,et al.  Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Individuals with Early Alzheimer's Disease: Amyloid Imaging Positron Emission Tomography and Safety Results from a Phase 2 Study. , 2016, The journal of prevention of Alzheimer's disease.

[108]  D. Holtzman,et al.  Impaired Autophagy in APOE4 Astrocytes. , 2016, Journal of Alzheimer's disease : JAD.

[109]  J. L. Santos,et al.  Control of polymeric nanoparticle size to improve therapeutic delivery. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[110]  S. Kile,et al.  IVIG treatment of mild cognitive impairment due to Alzheimer's disease: a randomised double-blinded exploratory study of the effect on brain atrophy, cognition and conversion to dementia , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[111]  O. Abdallah,et al.  Novel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer’s disease: pharmaceutical, biological, and toxicological studies , 2015, International journal of nanomedicine.

[112]  N. Raz,et al.  Appraising the Role of Iron in Brain Aging and Cognition: Promises and Limitations of MRI Methods , 2015, Neuropsychology Review.

[113]  S. An,et al.  Role of apolipoprotein E in neurodegenerative diseases , 2015, Neuropsychiatric disease and treatment.

[114]  G. Baillie,et al.  The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease , 2015, Future science OA.

[115]  R. Riek,et al.  Structure based aggregation studies reveal the presence of helix-rich intermediate during α-Synuclein aggregation , 2015, Scientific Reports.

[116]  R. Daneman,et al.  The blood-brain barrier. , 2015, Cold Spring Harbor perspectives in biology.

[117]  Prakash Khadka,et al.  Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability , 2014 .

[118]  Laixiang Lin,et al.  Feasibility of β-Sheet Breaker Peptide-H102 Treatment for Alzheimer's Disease Based on β-Amyloid Hypothesis , 2014, PloS one.

[119]  M. Masserini,et al.  Liposomes bi-functionalized with phosphatidic acid and an ApoE-derived peptide affect Aβ aggregation features and cross the blood-brain-barrier: implications for therapy of Alzheimer disease. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[120]  Youfu Wang,et al.  Carbon quantum dots: synthesis, properties and applications , 2014 .

[121]  Jurgen A. H. R. Claassen,et al.  β-secretase inhibitor; a promising novel therapeutic drug in Alzheimer’s disease , 2014, Front. Aging Neurosci..

[122]  Viney Lather,et al.  Dendrimers in drug delivery and targeting: Drug-dendrimer interactions and toxicity issues , 2014, Journal of pharmacy & bioallied sciences.

[123]  A. Chacko,et al.  Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier , 2014, Perspectives in medicinal chemistry.

[124]  Charles Duyckaerts,et al.  Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. , 2014, European journal of medicinal chemistry.

[125]  G. Bu,et al.  The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer’s disease , 2014, Front. Aging Neurosci..

[126]  Anton P. J. Middelberg,et al.  Towards designer nanoemulsions for precision delivery of therapeutics , 2014 .

[127]  J. Nam,et al.  Amyloid-β aggregation with gold nanoparticles on brain lipid bilayer. , 2014, Small.

[128]  Rupesh Dudhe,et al.  Nanoemulsion: an advanced mode of drug delivery system , 2014, 3 Biotech.

[129]  Young Chul Youn,et al.  The genetics of Alzheimer’s disease , 2014, Clinical interventions in aging.

[130]  H. Ji,et al.  Involvement of cysteinyl leukotriene receptor 1 in Aβ1–42-induced neurotoxicity in vitro and in vivo , 2014, Neurobiology of Aging.

[131]  W. Wan,et al.  The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer's disease , 2014, The International journal of neuroscience.

[132]  Ajay-Vikram Singh,et al.  Nanoparticle enabled drug delivery across the blood brain barrier: in vivo and in vitro models, opportunities and challenges. , 2014, Current pharmaceutical biotechnology.

[133]  Qizhi Zhang,et al.  Dual-functional nanoparticles targeting amyloid plaques in the brains of Alzheimer's disease mice. , 2014, Biomaterials.

[134]  E. Masliah,et al.  Structural diversity of Alzheimer's disease amyloid-β dimers and their role in oligomerization and fibril formation. , 2014, Journal of Alzheimer's disease : JAD.

[135]  T. Hartmann,et al.  Neprilysin and Aβ Clearance: Impact of the APP Intracellular Domain in NEP Regulation and Implications in Alzheimer’s Disease , 2013, Front. Aging Neurosci..

[136]  T. Golde,et al.  γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.

[137]  M. Stefani,et al.  Protein Folding and Aggregation into Amyloid: The Interference by Natural Phenolic Compounds , 2013, International journal of molecular sciences.

[138]  Soodabeh Davaran,et al.  Liposome: classification, preparation, and applications , 2013, Nanoscale Research Letters.

[139]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[140]  C. Eckman,et al.  Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[141]  D. Michaelson,et al.  ApoE4 induces Aβ42, tau, and neuronal pathology in the hippocampus of young targeted replacement apoE4 mice , 2013, Molecular Neurodegeneration.

[142]  J. Dumin,et al.  Efficacy of SPI-1865, a novel gamma-secretase modulator, in multiple rodent models , 2013, Alzheimer's Research & Therapy.

[143]  Hong-Qi Yang,et al.  Current advances in the treatment of Alzheimer's disease: focused on considerations targeting Aβ and tau , 2012, Translational Neurodegeneration.

[144]  Linfeng Wu,et al.  β-cyclodextrin-poly(β-amino ester) nanoparticles for sustained drug delivery across the blood-brain barrier. , 2012, Biomacromolecules.

[145]  B. Hyman,et al.  Soluble forms of tau are toxic in Alzheimer’s disease , 2012, Translational neuroscience.

[146]  I. Deary,et al.  The role of ECE1 variants in cognitive ability in old age and Alzheimer's disease risk , 2012, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[147]  Tim West,et al.  Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis , 2012, Proceedings of the National Academy of Sciences.

[148]  K. Blennow,et al.  Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. , 2012, Archives of neurology.

[149]  L. Mucke,et al.  Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. , 2012, Cold Spring Harbor perspectives in medicine.

[150]  W. Scheper,et al.  PEGylated nanoparticles bind to and alter amyloid-beta peptide conformation: toward engineering of functional nanomedicines for Alzheimer's disease. , 2012, ACS nano.

[151]  L. Chew,et al.  The Toxicity of Amyloid β Oligomers , 2012, International journal of molecular sciences.

[152]  D. Selkoe,et al.  Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[153]  Laura M Ensign,et al.  Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. , 2012, Advanced drug delivery reviews.

[154]  Bernardo L Sabatini,et al.  Synapses and Alzheimer's disease. , 2012, Cold Spring Harbor perspectives in biology.

[155]  S. Jo,et al.  Mechanisms of Amyloid-β Peptide Clearance: Potential Therapeutic Targets for Alzheimer’s Disease , 2012, Biomolecules & therapeutics.

[156]  C. Borchers,et al.  Structure and dynamics of small soluble Aβ(1-40) oligomers studied by top-down hydrogen exchange mass spectrometry. , 2012, Biochemistry.

[157]  Nick C Fox,et al.  Brain imaging in Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[158]  T. Maekawa,et al.  Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease , 2012, PloS one.

[159]  M. Grimaldi,et al.  The iAβ5p β-breaker peptide regulates the Aβ(25-35) interaction with lipid bilayers through a cholesterol-mediated mechanism. , 2012, Biochemical and biophysical research communications.

[160]  L. Reijmers,et al.  Natural Amyloid-Beta Oligomers Acutely Impair the Formation of a Contextual Fear Memory in Mice , 2012, PloS one.

[161]  Sterling C. Johnson,et al.  The effects of ramipril in individuals at risk for Alzheimer's disease: results of a pilot clinical trial. , 2012, Journal of Alzheimer's disease : JAD.

[162]  A. Lönneborg.  Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood , 2012, Molecular Diagnosis & Therapy.

[163]  Linda Zhang,et al.  Current neuroimaging techniques in Alzheimer's disease and applications in animal models. , 2012, American journal of nuclear medicine and molecular imaging.

[164]  L. Breydo,et al.  Vaccination with a non-human random sequence amyloid oligomer mimic results in improved cognitive function and reduced plaque deposition and micro hemorrhage in Tg2576 mice , 2012, Molecular Neurodegeneration.

[165]  D. I. Lewis,et al.  Effect of Sodium Valproate Administration on Brain Neprilysin Expression and Memory in Rats , 2012, Journal of Molecular Neuroscience.

[166]  R. Rodriguiz,et al.  Mice deficient in endothelin‐converting enzyme‐2 exhibit abnormal responses to morphine and altered peptide levels in the spinal cord , 2011, Journal of neurochemistry.

[167]  Anand Viswanathan,et al.  Cerebral amyloid angiopathy in the elderly , 2011, Annals of neurology.

[168]  E. Génin,et al.  No replication of genetic association between candidate polymorphisms and Alzheimer's disease , 2011, Neurobiology of Aging.

[169]  R. Tycko.  Solid-state NMR studies of amyloid fibril structure. , 2011, Annual review of physical chemistry.

[170]  D. Hinton,et al.  Protein Kinase C-Regulated Aβ Production and Clearance , 2011, International journal of Alzheimer's disease.

[171]  Kaj Blennow,et al.  Cerebrospinal fluid protein biomarkers for Alzheimer’s disease , 2004, NeuroRX.

[172]  J. Dunys,et al.  γ-Secretase-mediated regulation of neprilysin: influence of cell density and aging and modulation by imatinib. , 2011, Journal of Alzheimer's disease : JAD.

[173]  D. Kovacs,et al.  The many substrates of presenilin/γ-secretase. , 2011, Journal of Alzheimer's disease : JAD.

[174]  M. Owen,et al.  A multi-center study of ACE and the risk of late-onset Alzheimer's disease. , 2011, Journal of Alzheimer's disease : JAD.

[175]  Ruth Nussinov,et al.  β-Barrel topology of Alzheimer's β-amyloid ion channels. , 2010, Journal of molecular biology.

[176]  Sandip S Chavhan,et al.  Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[177]  Wenwei Tang,et al.  Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. , 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[178]  A. Ludolph,et al.  Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells. , 2010, Stem cells and development.

[179]  K. Dawson,et al.  Dual effect of amino modified polystyrene nanoparticles on amyloid β protein fibrillation. , 2010, ACS chemical neuroscience.

[180]  D. Kaplan,et al.  Mechanisms of enzymatic degradation of amyloid Beta microfibrils generating nanofilaments and nanospheres related to cytotoxicity. , 2010, Biochemistry.

[181]  D. Connor,et al.  The Alzheimer's questionnaire: a proof of concept study for a new informant-based dementia assessment. , 2010, Journal of Alzheimer's disease : JAD.

[182]  George Perry,et al.  Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. , 2010, Biochimica et biophysica acta.

[183]  Gregory J Brewer,et al.  Amyloid-β as a modulator of synaptic plasticity. , 2010, Journal of Alzheimer's disease : JAD.

[184]  D. Walsh,et al.  Alzheimer's disease: synaptic dysfunction and Aβ , 2009, Molecular Neurodegeneration.

[185]  T. Wyss-Coray,et al.  The p75 Neurotrophin Receptor Promotes Amyloid-β(1-42)-Induced Neuritic Dystrophy In Vitro and In Vivo , 2009, The Journal of Neuroscience.

[186]  Yong Shen,et al.  Searching for Disease Modifiers—PKC Activation and HDAC Inhibition—A Dual Drug Approach to Alzheimer's Disease that Decreases Aβ Production while Blocking Oxidative Stress , 2009, ChemMedChem.

[187]  S. Love,et al.  Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. , 2009, The American journal of pathology.

[188]  S. Mukherjee,et al.  Solid Lipid Nanoparticles: A Modern Formulation Approach in Drug Delivery System , 2009, Indian journal of pharmaceutical sciences.

[189]  E. Siemers,et al.  Development of semagacestat (LY450139), a functional γ-secretase inhibitor, for the treatment of Alzheimer's disease , 2009, Expert Opinion on Pharmacotherapy.

[190]  Rajesh Singh,et al.  Nanoparticle-based targeted drug delivery. , 2009, Experimental and molecular pathology.

[191]  Hong-Qi Yang,et al.  Involvement of protein trafficking in deprenyl-induced alpha-secretase activity regulation in PC12 cells. , 2009, European journal of pharmacology.

[192]  S. Mandel,et al.  Simultaneous Manipulation of Multiple Brain Targets by Green Tea Catechins: A Potential Neuroprotective Strategy for Alzheimer and Parkinson Diseases , 2008, CNS neuroscience & therapeutics.

[193]  Khadija Iqbal,et al.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease. , 2008, Current medicinal chemistry.

[194]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[195]  R. Rodriguiz,et al.  Animals lacking endothelin‐converting enzyme‐2 are deficient in learning and memory , 2008, Genes, brain, and behavior.

[196]  S. Hendrix,et al.  Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.

[197]  G. Bitan,et al.  Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. , 2008, Current Alzheimer research.

[198]  J. Lau,et al.  Angiotensin-converting enzyme insertion/deletion gene polymorphic variant as a marker of coronary artery disease: a meta-analysis. , 2008, Archives of internal medicine.

[199]  E. Powers,et al.  Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation. , 2008, Biophysical journal.

[200]  S. Gauthier,et al.  Alzhemed: a potential treatment for Alzheimer's disease. , 2007, Current Alzheimer research.

[201]  F. Maxfield,et al.  Activation of microglia acidifies lysosomes and leads to degradation of Alzheimer amyloid fibrils. , 2007, Molecular biology of the cell.

[202]  A. Lustig,et al.  Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. , 2007, Experimental cell research.

[203]  D. Blacker,et al.  Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database , 2007, Nature Genetics.

[204]  L. Liaudet,et al.  Nitric oxide and peroxynitrite in health and disease. , 2007, Physiological reviews.

[205]  Michael H. Hecht,et al.  Generic hydrophobic residues are sufficient to promote aggregation of the Alzheimer's Aβ42 peptide , 2006, Proceedings of the National Academy of Sciences.

[206]  David M Holtzman,et al.  Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo , 2006, Nature Medicine.

[207]  L. Fenart,et al.  Methylated β-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood–brain barrier , 2006 .

[208]  F. Chiti.  Relative Importance of Hydrophobicity, Net Charge, and Secondary Structure Propensities in Protein Aggregation , 2006 .

[209]  A. Gliozzi,et al.  β-Amyloid Is Different in Normal Aging and in Alzheimer Disease* , 2005, Journal of Biological Chemistry.

[210]  B. Hyman,et al.  Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[211]  H. Arai,et al.  Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease , 2005, Annals of neurology.

[212]  Pritam Das,et al.  Diverse compounds mimic Alzheimer disease–causing mutations by augmenting Aβ42 production , 2005, Nature Medicine.

[213]  M. Kirkitadze,et al.  Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. , 2005, Acta biochimica Polonica.

[214]  J. Schwartz,et al.  Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease , 2004, Molecular Psychiatry.

[215]  L. Hersh,et al.  Estrogen regulates neprilysin activity in rat brain , 2004, Neuroscience Letters.

[216]  E. Godaux,et al.  A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.

[217]  S. Robinson,et al.  Physiological Roles of Amyloid-β and Implications for its Removal in Alzheimer’s Disease , 2004, Drugs & aging.

[218]  C. Dobson,et al.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution , 2003, Journal of Molecular Medicine.

[219]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[220]  Wickliffe C Abraham,et al.  Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory , 2003, Progress in Neurobiology.

[221]  L. Feuk,et al.  Haplotypes extending across ACE are associated with Alzheimer's disease. , 2003, Human molecular genetics.

[222]  W. Oertel,et al.  Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[223]  M. Rossor.  Contribution of cerebral amyloid angiopathy to Alzheimer ’ s disease , 2003 .

[224]  W. Gong,et al.  Potential role of the formyl peptide receptor‐like 1 (FPRL1) in inflammatory aspects of Alzheimer’s disease , 2002, Journal of leukocyte biology.

[225]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[226]  T. Saido,et al.  Generation of amyloid β peptide with pyroglutamate at position 3 in primary cortical neurons , 2002, Neuroscience Letters.

[227]  R. Doms,et al.  Glu11 site cleavage and N-terminally truncated A beta production upon BACE overexpression. , 2002, Biochemistry.

[228]  T. Iwatsubo,et al.  Neprilysin Degrades Both Amyloid β Peptides 1–40 and 1–42 Most Rapidly and Efficiently among Thiorphan- and Phosphoramidon-sensitive Endopeptidases* , 2001, The Journal of Biological Chemistry.

[229]  P. Mcgeer,et al.  Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide , 2001, Neuroscience Letters.

[230]  R. Katzman.,et al.  Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. , 2000, The Journal of clinical investigation.

[231]  R. Weller,et al.  Cerebral Amyloid Angiopathy: Accumulation of Aβ in Interstitial Fluid Drainage Pathways in Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[232]  J. Treanor,et al.  Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. , 1999, Science.

[233]  C. Parsons,et al.  Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.

[234]  H. Orzechowski,et al.  Human endothelin-converting enzyme-1 beta mRNA expression is regulated by an alternative promoter. , 1998, Journal of cardiovascular pharmacology.

[235]  R. Motter,et al.  Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease , 1997 .

[236]  M. Yanagisawa,et al.  Endothelin-converting Enzyme-2 Is a Membrane-bound, Phosphoramidon-sensitive Metalloprotease with Acidic pH Optimum (*) , 1995, The Journal of Biological Chemistry.

[237]  P. Powchick,et al.  Tacrine , 1995, The Lancet.